16th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2009, Montreal
8 June 2009. Related: Conference reports.
CROI 16 (Retrovirus) 2009
Assessing the cardiovascular impact of HIV, abacavir, and new signals for lopinavir/r
3 June 2009. Related: Conference reports, Side effects.
Intensive smoking cessation programme reports limited success at 6 months
3 June 2009. Related: Conference reports, Side effects.
HDL particle concentration predicts cardiovascular disease in SMART
3 June 2009. Related: Conference reports, Side effects.
No effect of hormonal contraception on HIV disease progression in large multi-country cohort
3 June 2009. Related: Conference reports, Women's health.
Pregnancy, family planning, and HIV acquisition in HPTN 039
3 June 2009. Related: Conference reports, Pregnancy.
Progression and regression of pre-malignant cervical lesions in HIV-positive women from Soweto
3 June 2009. Related: Conference reports.
CD4 count >250 not predictive of rash-associated hepatoxicity among women initiating nevirapine-based ART in Zambia, Thailand, and Kenya
3 June 2009. Related: Conference reports, Side effects.
HIV testing of infants at immunisation clinics in Kwazulu-Natal
3 June 2009. Related: Conference reports.
Rapid HIV disease progression in South African infants co-infected with cytomegalovirus (CMV)
3 June 2009. Related: Conference reports, Coinfections and complications.
Pharmacokinetic studies in very young infants
3 June 2009. Related: Conference reports, Paediatric care.
Double-dose lopinavir/ritonavir provides insufficient lopinavir exposure in children receiving rifampicin
3 June 2009. Related: Conference reports, Paediatric care, TB coinfection.
PI-based ART in children with HIV and HIV/TB coinfection in South Africa
3 June 2009. Related: Conference reports, Paediatric care, TB coinfection.
Etravirine dose selection in children aged 6 to 17
3 June 2009. Related: Conference reports, Paediatric care.
Preliminary results from first paediatric raltegravir study
3 June 2009. Related: Conference reports.
16th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2009, Montreal
30 April 2009. Related: Conference reports.
HIV infection in the brain: a long-term limitation of HAART?
26 April 2009. Related: Conference reports.
When to start HAART – a key research question with the least available data
26 April 2009. Related: Conference reports.
Major studies rule out any benefit of Interleukin-2 (IL-2): results from ESPRIT and SILCAAT
26 April 2009. Related: Conference reports.
Higher rates of non-AIDS cancers in HIV positive people
26 April 2009. Related: Conference reports, Cancer and HIV.
Effect of breast feeding vs formula feeding on maternal health
26 April 2009. Related: Conference reports, Pregnancy.
PEPI-Malawi
26 April 2009. Related: Conference reports, Pregnancy.
Premature delivery and mother-to-child HIV transmission: a risk/benefit analysis among women receiving HAART
20 April 2009. Related: Conference reports, Pregnancy.
Risk factors for adverse pregnancy outcomes in Botswana
20 April 2009. Related: Conference reports, Pregnancy.
Higher risk of transmission with delayed control of maternal viral load despite viral loads of <500 copies/mL at delivery
20 April 2009. Related: Conference reports, Pregnancy.
Lopinavir/r containing regimen superior to nevirapine containing regimen in women previously exposed to single dose nevirapine
20 April 2009. Related: Conference reports, Pregnancy.
Covering the nevirapine tail
20 April 2009. Related: Conference reports, Pregnancy.
Effect of single dose nevirapine on subsequent nevirapine-containing HAART: long term outcomes
20 April 2009. Related: Conference reports, Pregnancy.
High rates of HIV acquisition in pregnancy and post partum in Francistown, Botswana
20 April 2009. Related: Conference reports, Pregnancy.
Children on HAART do extremely well at South African clinic
20 April 2009. Related: Conference reports, Paediatric care.
New boosting alternatives to ritonavir: GS-99350 and SPI-452
20 April 2009. Related: Conference reports.
Interactions with raltegravir: with twice-daily atazanavir and standard dose lamotrigine
20 April 2009. Related: Conference reports.
Effect of tenofovir on abacavir phosphorylation
20 April 2009. Related: Conference reports, PK and drug interactions.
Nevirapine: fluconazole and TB treatment
20 April 2009. Related: Conference reports, TB coinfection.
PI interactions: lopinavir/rifampicin, saquinavir, atazanavir/tenofovir in pregnancy
20 April 2009. Related: Conference reports, PK and drug interactions.
Identification of drug interactions in clinical practice
20 April 2009. Related: Conference reports.
Effect of substance abuse on ART pharmacokinetics
20 April 2009. Related: Conference reports.